MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients

Summary

While many people with COVID-19 suffer from respiratory disease, there is growing evidence that the virus also affects other organs. The purpose of this study is to better understand the effects of COVID-19 on the lungs and other organs.

The study investigators have developed new techniques in Magnetic Resonance Imaging (MRI) to scan the lungs, heart, brain and liver. The study investigators hope to learn more about how the virus causes inflammation in these organs and how this inflammation changes over time as people recover from COVID-19 illness.

The study aims to enroll 228 people in Alberta. Participants will undergo one or more MRI scans and have blood testing at one or more time points to assess for inflammation, kidney function, liver function and possible heart injury. Participants will also undergo testing to assess sense of smell, cognition (thinking and memory), spirometry (breathing test for lung function) and and exercise tolerance (walk test).

The study investigators hope this study will help us learn more about the long-term risks of COVID-19 disease.

Conditions

• Covid19
• Coronavirus Infection
• SARS-CoV Infection

Interventions

DIAGNOSTIC_TEST

MRI (heart, brain, lungs, liver)

MRI (heart, brain, lungs, liver)

DIAGNOSTIC_TEST

Bloodwork

Serum biomarkers to assess systemic inflammation, renal function, cardiac injury, liver injury and steatosis, ACE-2 related peptides, cytokines, Activin A and autoantibodies to cardiac antigens, humoral cell RNA

OTHER

Cognitive testing

NIH toolbox Cognitive Measures

OTHER

Olfaction testing

Brief Smell Identification Test (BSIT)

DIAGNOSTIC_TEST

Spirometry

Spirometry to evaluate forced expiratory volume in 1 second and forced vital capacity

OTHER

Walk Test

Walk test to record overall distance walked in 6 minutes and time taken to walk the first 25 feet

Sponsors & Collaborators

• Canadian VIGOUR Centre

  collaborator OTHER

• University of Alberta

  lead OTHER

Principal Investigators

• Ian Paterson, MD · University of Alberta

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-11-12

Primary Completion

2021-09-22

Completion

2022-09-30

Countries

• Canada

Study Locations